174 completed. 174 Phase 1, 47 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 174 | Completed 174 |
| Phase 2 | 47 | Completed 47 |
Follow Blood Coagulation Disorders: new trials by email Literature Review of Blood Coagulation Disorders trials Research Report on Blood Coagulation Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People NNC0442-0344 A - Haemophilia A | Phase 1 | Completed | Novo Nordisk A/S | 80 | 2025-11-18 | 2026-06-17 |
| A Study to Assess the Safety and Effects of Different Doses of an Investigational Drug, BAY 3389934, in Healthy Japanese Volunteers. BAY 3389934, Matching Placebo / Diluent - Sepsis Associated Disseminated Intravascular Coagulation (DIC) | Phase 1 | Completed | Bayer | 16 | 2025-09-22 | 2026-06-05 |
| Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP) PN20 treatment - Primary Immune Thrombocytopenia (ITP) | Phase 1 | Completed | Chongqing Peg-Bio Biopharm Co., Ltd. | 12 | 2025-03-07 | 2026-10-21 |
| Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A Efanesoctocog alfa - Hemophilia A | Phase 1 | Completed | Swedish Orphan Biovitrum | 24 | 2025-02-24 | 2026-06-25 |
| A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy Men NNC0442-0344 A, Placebo - Haemophilia A | Phase 1 | Completed | Novo Nordisk A/S | 95 | 2024-09-23 | 2026-04-01 |
| The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects STSA-1301 subcutaneous injection, Placebo - Primary Immune Thrombocytopenia | Phase 1 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 36 | 2023-11-16 | 2024-08-12 |
| SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment SS109 - Male, Hemophilia A With Inhibitor | Phase 1 / Phase 2 | Completed | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 24 | 2023-10-12 | 2024-07-19 |
| Study of TU7710 in Warfarin Anti-coagulated Healthy Male Subjects TU7710, Normal saline - Hemophilia a, Hemophilia B | Phase 1 | Completed | TiumBio Co., Ltd. | 40 | 2023-08-02 | 2024-09-27 |
| An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4) Povetacicept - Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia | Phase 1 / Phase 2 | Completed | Alpine Immune Sciences Inc, A Subsidiary of Vertex | 30 | 2023-07-03 | 2026-09-14 |
| A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and Cartridge NNC0365-3769 (Mim8) - Haemophilia A | Phase 1 | Completed | Novo Nordisk A/S | 205 | 2023-01-02 | 2025-10-14 |
| A Phase I of SS109 in Hemophilia A or and B With Inhibitors SS109 - Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Phase 1 | Completed | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 27 | 2022-12-14 | 2023-08-22 |
| A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient MG1113 - Hemophilia | Phase 1 | Completed | GC Biopharma Corp | 15 | 2022-08-24 | 2025-11-24 |
| A Study of PN20 in Healthy Adult Volunteers PN20, Placebo - Chemotherapy-induced Thrombocytopenia, Immune Thrombocytopenic Purpura | Phase 1 | Completed | Chongqing Peg-Bio Biopharm Co., Ltd. | 27 | 2022-06-16 | 2025-03-13 |
| Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene - Hemophilia A | Phase 1 | Completed | Christian Medical College, Vellore, India | 6 | 2022-04-01 | 2024-07-12 |
| A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor STSP-0601 for Injection - Hemophilia | Phase 1 / Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 77 | 2021-10-12 | 2024-09-19 |
| Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A Efanesoctocog alfa, Octocog alfa, Rurioctocog alfa pegol - Hemophilia A | Phase 1 | Completed | Sanofi | 13 | 2021-08-11 | 2025-09-18 |
| A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection ADVATE, FRSW117 - Severe Hemophilia A | Phase 1 | Completed | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 13 | 2021-06-22 | 2023-09-08 |
| A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection ADVATE, FRSW107 - Hemophilia A | Phase 1 | Completed | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 13 | 2021-06-16 | 2023-08-22 |
| To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD) efanesoctocog alfa (BIVV001) - Von Willebrand's Disease (VWD) | Phase 1 | Completed | Bioverativ, a Sanofi company | 6 | 2021-05-03 | 2025-09-25 |
| Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia PF-06741086 - Severe Hemophilia | Phase 1 | Completed | Pfizer | 6 | 2021-04-16 | 2023-07-07 |
Showing 20 of 174. Sign in to see all of them.
Hemophilia A (69) · Thrombocythemia, Essential (43) · Polycythemia Vera (38) · Primary Myelofibrosis (37) · Myeloproliferative Disorders (35) · Hemophilia B (31) · Leukemia, Myeloid, Acute (31) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (28) · Leukemia, Myelomonocytic, Chronic (25) · Leukemia, Lymphocytic, Chronic, B-Cell (24) · Myelodysplastic Syndromes (24) · Leukemia (23) · Multiple Myeloma (23) · Burkitt Lymphoma (22) · Lymphoma, B-Cell, Marginal Zone (21)
Hemic and Lymphatic Diseases (174) · Hematologic Diseases (162) · Hemorrhagic Disorders (159) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (117) · Genetic Diseases, Inborn (98) · Blood Coagulation Disorders, Inherited (96) · Coagulation Protein Disorders (83) · Blood Platelet Disorders (69) · Pathological Conditions, Signs and Symptoms (67) · Pathologic Processes (66) · Immune System Diseases (62) · Bone Marrow Diseases (42) · Neoplasms (42) · Thrombocytosis (42)
Factor VIII (15) · Peripheral Blood Stem Cell Transplantation (8) · Cyclosporine (6) · eltrombopag (6) · Busulfan (5) · Cyclophosphamide (5) · F8 protein, human (5) · Injections (5) · fludarabine phosphate (5) · recombinant factor VIII N8 (5) · Antilymphocyte Serum (4) · BIVV001 (4) · Filgrastim (4) · Methotrexate (4) · BAX 855 (3)
Novo Nordisk A/S (24) · Bayer (11) · National Cancer Institute (NCI) (7) · GlaxoSmithKline (6) · Baxalta now part of Shire (5) · Eisai Inc. (4) · Fred Hutchinson Cancer Center (4) · Hangzhou Gensciences Biopharmaceutical Co., Ltd. (4) · Pfizer (4) · Bioverativ Therapeutics Inc. (3) · Bioverativ, a Sanofi company (3) · CSL Behring (3) · Eli Lilly and Company (3) · Staidson (Beijing) Biopharmaceuticals Co., Ltd (3) · Amgen (2)
United States (93) · United Kingdom (34) · Germany (31) · Spain (17) · Bulgaria (16) · China (16) · Italy (15) · France (14) · Israel (10) · Japan (10) · Netherlands (9) · Australia (8) · Austria (8) · Canada (8) · Denmark (8)
Franklin Johnson (2) · Gilbert C. White (2) · Iris Jacobs, MD (2) · Jacob H Grauslund, MD (2) · Lei Zhang (2) · Nancy Whiting, PharmD (2)
PMID 25495795, PMID 17880439, PMID 35075289, PMID 36796484, PMID 39642315, PMID 40386832, PMID 12752100, PMID 1374895, PMID 15230949, PMID 1538192, PMID 15570084, PMID 15577929, PMID 15870545, PMID 16375711, PMID 17961193, PMID 19138379, PMID 19208097, PMID 19372317, PMID 20133895, PMID 21443634, PMID 22110246, PMID 22149959, PMID 22223821, PMID 22259028, PMID 22353395, PMID 22859609, PMID 23398640, PMID 23777763, PMID 24474568, PMID 24559067, PMID 24843882, PMID 24846496, PMID 25409372, PMID 25426834, PMID 25641556, PMID 25762180, PMID 26093876, PMID 26157075, PMID 26210442, PMID 26504182, PMID 26853648, PMID 27140804, PMID 27170068, PMID 27479177, PMID 28005225, PMID 28601434, PMID 28691885, PMID 28716862, PMID 28934680, PMID 29224506
2015 (7), 2009 (5), 2014 (5), 2018 (3), 2023 (3), 2005 (2), 2008 (2), 2016 (2), 2017 (2), P30CA015083 (2), U01CA062491 (2), 2019 (1), P01CA018029 (1), P30CA006973 (1), P30CA016058 (1)